Alpha 1 Antitrypsin Deficiency clinical trials

Explore recruiting alpha 1 antitrypsin deficiency clinical trials.

Recruiting alpha 1 antitrypsin deficiency studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Alpha 1 Antitrypsin Deficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1 Study of AIR-001 in Adults with AATD.

Sweden, Ireland, Spain, Netherlands, Portugal, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants with AATD Pi*ZZ on WVE-006 (RestorAATion-2)

Finland, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Austria, Germany, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety and clinical parameter assessment of a 12-week home self-infusion therapy with Prolastin® in patients with severe alpha-1-antitrypsin (AATD) deficiency. The “Sunshine Study”

Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-label, Multicenter, Randomized, Non-Inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Weekly Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Patients with Alpha1-Antitrypsin Deficiency Compared to Corresponding Standard 60 mg/kg/week and 120 mg/kg/week Doses of Intravenous Alpha1-Proteinase Inhibitor (5%)

Poland, Denmark, Netherlands, Ireland, Sweden, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Single-Arm, Open-Label Extension Study, Evaluating the Long-Term Safety and Clinical Efficacy of SAR447537 (INBRX-101) in Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysema

Spain, Sweden, Denmark, Poland, Ireland

Therapeutic exploratory (Phase II) EU CTIS Study details

Alpha 1 Antitrypsin Deficiency trials by city

Alpha 1 Antitrypsin Deficiency in Toronto Alpha 1 Antitrypsin Deficiency in Vancouver Alpha 1 Antitrypsin Deficiency in Montreal Alpha 1 Antitrypsin Deficiency in Calgary Alpha 1 Antitrypsin Deficiency in Edmonton Alpha 1 Antitrypsin Deficiency in Ottawa Alpha 1 Antitrypsin Deficiency in Winnipeg Alpha 1 Antitrypsin Deficiency in Quebec City Alpha 1 Antitrypsin Deficiency in Hamilton Alpha 1 Antitrypsin Deficiency in Kitchener Alpha 1 Antitrypsin Deficiency in London Alpha 1 Antitrypsin Deficiency in Halifax Alpha 1 Antitrypsin Deficiency in New York Alpha 1 Antitrypsin Deficiency in Los Angeles Alpha 1 Antitrypsin Deficiency in Chicago Alpha 1 Antitrypsin Deficiency in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease